Global Glioblastoma Multiforme Therapeutics Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Glioblastoma Multiforme Therapeutics Market Research Report 2024
Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor.
According to Mr Accuracy reports’s new survey, global Glioblastoma Multiforme Therapeutics market is projected to reach US$ 996.4 million in 2034, increasing from US$ 548.3 million in 2024, with the CAGR of 8.8% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Glioblastoma Multiforme Therapeutics market research.
Currently unavailable therapies and prognosis for the treatment of GBM is expected to impact the market growth positively through to 2024. Presence of the treatment options which do not increase the overall survival rate in patients such as surgical resection, which is followed by chemotherapy and radiotherapy, is another factor attributing towards the expected growth of this market. Moreover, the fact that glioma stem cells resist conventional treatments also raises urgent need for alternative treatment therapies for glioblastoma multiforme thus driving the market. Increasing R&D in gene therapy and molecular biotechnology for the treatment of CNS associated disorders and cancer is anticipated to fuel the market growth over the forecast period. However, high expenditure involved in research employing genomics based research is a key restraint for market.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Glioblastoma Multiforme Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Arbor Pharmaceuticals
Bristol-Myers Squibb
Eisai
F. Hoffmann-La Roche
Merck
Segment by Type
Temozolomide
Bevacozumab
Carmustine
Hospitals
Clinics
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Glioblastoma Multiforme Therapeutics report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Glioblastoma Multiforme Therapeutics market is projected to reach US$ 996.4 million in 2034, increasing from US$ 548.3 million in 2024, with the CAGR of 8.8% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Glioblastoma Multiforme Therapeutics market research.
Currently unavailable therapies and prognosis for the treatment of GBM is expected to impact the market growth positively through to 2024. Presence of the treatment options which do not increase the overall survival rate in patients such as surgical resection, which is followed by chemotherapy and radiotherapy, is another factor attributing towards the expected growth of this market. Moreover, the fact that glioma stem cells resist conventional treatments also raises urgent need for alternative treatment therapies for glioblastoma multiforme thus driving the market. Increasing R&D in gene therapy and molecular biotechnology for the treatment of CNS associated disorders and cancer is anticipated to fuel the market growth over the forecast period. However, high expenditure involved in research employing genomics based research is a key restraint for market.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Glioblastoma Multiforme Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Arbor Pharmaceuticals
Bristol-Myers Squibb
Eisai
F. Hoffmann-La Roche
Merck
Segment by Type
Temozolomide
Bevacozumab
Carmustine
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Glioblastoma Multiforme Therapeutics report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices